Startseite
Kongressberichte 2018
23rd Congress of EHA
Important AML Presentations
IDHm and BCL2 inhibitors in AML
IDHm and BCL2 inhibitors in AML
Daniel A. Pollyea, et al. ABSTRACT
Conclusion
In a high-risk, molecularly defined R/R AML patient population, IVO induced durable remissions and was well tolerated. Studies in previously untreated AML populations are ongoing.
(S1561) ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)
Daniel A. Pollyea, et al. ABSTRACT
Conclusion
Enasidenib induced hematologic responses in approximately one-third of these older pts with previously untreated mIDH2 AML who were not candidates for standard Tx, and more than one-half of whom had an AHD. Approximately 1 in 5 of these pts attained CR during enasidenib monotherapy. Responses were durable: median duration of any response was not reached. Median OS was also promising (11.3 months) in this cohort with median age 77 years; pts aged >65 have an estimated median OS of only ~5 months, even when treated (Medeiros, Ann Hematol, 2015). Tx-related TEAEs were infrequent and led to discontinuation for only 2 pts. These results suggest enasidenib may benefit older adults with mIDH2 AML who are not fit to receive cytotoxic regimens. Enasidenib is under study in a similar AML patient population in the Beat AML Master Trial (NCT03013998).
(S1562) MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Courtney D., et al. ABSTRACT
Conclusion
mIDH inhibitor + AZA regimens were generally well tolerated in these older pts with ND-AML; 65% of pts remained on-study at data cutoff. The most common AEs were grade 1-2 gastrointestinal events and enasidenib-related indirect bilirubin elevations, likely due to off-target inhibition of the UGT1A1 enzyme. Response rates are encouraging. Phase 1b enrollment completed in late 2017; updated data for all 23 ivosidenib and 6 enasidenib pts will be presented, as well as longitudinal changes in mIDH variant allele frequencies. Enrollment continues in the phase 2 portion of this study (enasidenib + AZA) and in the phase 3 AGILE study of ivosidenib+ AZA (NCT03173248).
(S1563) DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Courtney D., et al. ABSTRACT
Conclusion
Preliminary data suggest that 400 mg of VEN has the optimal benefit-risk profile in combination with DEC or AZA, which demonstrated a tolerable safety profile with deep responses and durable outcomes in elderly patients with AML.
Andrew H. Wei, et al. ABSTRACT
Conclusion
To date, the MTD has not been reached with VEN up to 600mg in combination with 5+2 chemotherapy in fit older patients with AML. The overall CR/CRi rate is 71%. Analyses for response duration and survival are ongoing.